Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18506215 | 0.90 | USP30 (0.40) | USP30PRMT5WDR77CHEK2HCRTR1 | |
| SCHEMBL16948373 | 0.90 | USP30 (0.40) | USP30PRMT5WDR77CHEK2HCRTR1 | |
| SCHEMBL19792171 | 0.85 | USP30 (0.38) | USP30PRMT5WDR77CHEK2HCRTR1 | |
| SCHEMBL19702001 | 0.84 | USP30 (0.38) | USP30PRMT5WDR77CHEK2HCRTR1 | |
| SCHEMBL14929987 | 0.84 | USP30 (0.38) | USP30PRMT5WDR77CHEK2HCRTR1 | |
| SCHEMBL2707099 | 0.84 | HCRTR1 (0.44) | USP30HCRTR1HCRTR2 | |
| SCHEMBL1293568 | 0.84 | HCRTR1 (0.44) | USP30HCRTR1HCRTR2 | |
| SCHEMBL203117 | 0.84 | HCRTR1 (0.44) | USP30HCRTR1HCRTR2 | |
| SCHEMBL14053225 | 0.84 | USP30 (0.39) | USP30PRMT5WDR77CHEK2HCRTR1 | |
| SCHEMBL14053226 | 0.84 | USP30 (0.39) | USP30PRMT5WDR77CHEK2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044140-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044140-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SLC10A1, CYP7A1, CYP3A43 | USP30 2180/4885PRMT5 3092/4885WDR77 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.